Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
- Chief executive
- Dr. David Scott Zaccardelli Pharm.D.
- Employees
- 209
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- IPO date
- 2017-04-27
Profile observed 2026-07-04 16:00:48.315481+00 via eodhd.
Forecasts for Verona Pharma PLC ADR
This governed entity is ready for forecast-target bindings, but no public forecast collection is linked yet.
Identifiers & semantic identity
External identifiers, stable Library identity, and semantic-web assertions describe the same governed entity.
- iPulse entity ID
- fundsubj_ba61ef04-008f-585e-8a62-738568f6369f
- Wikidata ID
- No verified external match
- Google Knowledge Graph MID
- No verified external match